全文获取类型
收费全文 | 5588篇 |
免费 | 444篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 129篇 |
妇产科学 | 156篇 |
基础医学 | 815篇 |
口腔科学 | 121篇 |
临床医学 | 516篇 |
内科学 | 1123篇 |
皮肤病学 | 89篇 |
神经病学 | 541篇 |
特种医学 | 172篇 |
外科学 | 605篇 |
综合类 | 125篇 |
一般理论 | 4篇 |
预防医学 | 648篇 |
眼科学 | 223篇 |
药学 | 355篇 |
中国医学 | 13篇 |
肿瘤学 | 354篇 |
出版年
2021年 | 92篇 |
2020年 | 50篇 |
2019年 | 83篇 |
2018年 | 95篇 |
2017年 | 70篇 |
2016年 | 65篇 |
2015年 | 71篇 |
2014年 | 106篇 |
2013年 | 176篇 |
2012年 | 238篇 |
2011年 | 277篇 |
2010年 | 162篇 |
2009年 | 155篇 |
2008年 | 222篇 |
2007年 | 237篇 |
2006年 | 265篇 |
2005年 | 275篇 |
2004年 | 285篇 |
2003年 | 270篇 |
2002年 | 237篇 |
2001年 | 166篇 |
2000年 | 164篇 |
1999年 | 146篇 |
1998年 | 67篇 |
1997年 | 56篇 |
1996年 | 43篇 |
1995年 | 48篇 |
1994年 | 58篇 |
1993年 | 57篇 |
1992年 | 107篇 |
1991年 | 119篇 |
1990年 | 107篇 |
1989年 | 89篇 |
1988年 | 94篇 |
1987年 | 94篇 |
1986年 | 93篇 |
1985年 | 69篇 |
1984年 | 66篇 |
1983年 | 54篇 |
1982年 | 57篇 |
1981年 | 48篇 |
1980年 | 61篇 |
1979年 | 55篇 |
1978年 | 65篇 |
1977年 | 61篇 |
1976年 | 49篇 |
1974年 | 55篇 |
1973年 | 49篇 |
1972年 | 40篇 |
1971年 | 34篇 |
排序方式: 共有6045条查询结果,搜索用时 15 毫秒
991.
992.
Mark Fleisher Jan Marsal Scott D. Lee Laura E. Frado Alyssa Parian Burton I. Korelitz Brian G. Feagan 《Digestive diseases and sciences》2018,63(4):825-833
Background
Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action.Aims
This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action.Methods
We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.Results
Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease.Conclusions
These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.993.
Wilkens Justin L. McQueen Andrew D. LeMonte Joshua J. Suedel Burton C. 《Bulletin of environmental contamination and toxicology》2020,104(1):15-20
Bulletin of Environmental Contamination and Toxicology - Given the reported extent of microplastics in the aquatic environment, environmentally relevant exposure information for sediments dredged... 相似文献
994.
995.
The role of the miR‐200 family in epithelial–mesenchymal transition in colorectal cancer: a systematic review
下载免费PDF全文
![点击此处可从《International journal of cancer. Journal international du cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
996.
Zachary D. Horne Michael J. Dohopolski David A. Clump Steven A. Burton Dwight E. Heron 《Practical radiation oncology》2018,8(3):e117-e123
Purpose
Local failure following concurrent chemoradiation and in-lobe failures following stereotactic body radiation therapy (SBRT) are common. We evaluated our institutional experience using SBRT as salvage in this setting.Methods and materials
Seventy-two patients were reirradiated with SBRT for residual, locally recurrent, or new primary non-small cell lung cancer within or adjacent to a high-dose external beam radiation therapy or SBRT field. Kaplan-Meier analysis with log-rank test were used to estimate endpoints and differentiate cohorts.Results
Median follow-up was 17.9 months. Patients had residual or recurrent disease (54.2%); 45.8% had new lung primaries. Median reirradiated T size was 2.5 cm (range, 0.8-7.8 cm). Median pre-retreatment maximum standardized uptake value (SUVmax) was 7.15 (range, 1.2-37.6). The most common SBRT reirradiation regimen was 48 Gy in 4 fractions (range, 17-60 Gy in 1-5 fractions). Median progression-free survival was 15.2 months, and median overall survival was 20.8 months. Two-year local failure was 21.6%. Patients with SUVmax at reirradiation <7.0 had a 2-year local control of 93.1% versus 61.1% above the median (P < .001). The 2-year rate of distant metastases was 10.4% versus 54.1% in patients treated for a new primary versus residual or recurrent disease (P < .001). Median progression-free survival was 31.9 months versus 8.4 months, respectively (P = .037). Median survival of patients treated for new primary was 25.2 months versus 16.2 months with residual or recurrent disease (P = .049), and median survival for patients with reirradiation SUVmax below the median was 42.0 months versus 9.8 months above the median (P < .001). Acute any-grade toxicity was seen in 29.2% of patients, acute grade 3 toxicity in 11.1%, and late grade 3 toxicity in 1.4% with no treatment-related deaths.Conclusions
SBRT appears to be a safe and effective means of salvaging recurrent, residual, or new primary NSCLC in or adjacent to a previous high-dose radiation field. 相似文献997.
Kimmen Quan Philip Sutera Karen Xu Mark E. Bernard Steven A. Burton Rodney E. Wegner Herbert Zeh Nathan Bahary Ronald Stoller Dwight E. Heron 《Practical radiation oncology》2018,8(2):95-106
Purpose
Stereotactic ablative radiation therapy’s (SABR’s) great conformity and short duration has become an attractive treatment modality. We report a phase 2 clinical trial to evaluate efficacy and safety of induction chemotherapy (ICT) followed by SABR in patient with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).Methods and materials
Patients with biopsy-proven BR or LA PDAC were treated with four 21-day cycles of intravenous gemcitabine and oral capecitabine. Patients were restaged within 4 weeks after ICT by computed tomography and treated by 3-fraction SABR if no metastasis or progressive disease was identified. Patients were restaged 4 weeks following SABR to determine resectability. Tumor response was assessed with carbohydrate antigen 19-9.Results
Thirty-five patients (19 BR/16 LA) were enrolled. The median age was 71.8 years (range, 50.6-81.1). ICT was completed in 91.4% (n = 32) of patients. All patients who completed ICT completed SABR. Of those 32 patients, 34.3% (n = 12: 10 BR, 2 LA) underwent pancreaticoduodenectomy and 11 of 12 (91.7%) received R0 resection. Median overall survival was 18.8, 28.3, and 14.3 months for the entire cohort, BR, and LA, respectively. The 2-year local progression-free survival (LPFS) was 44.9%, 40%, and 52% for the entire cohort, BR, and LA, respectively. For BR patients, multivariate analysis showed surgery was associated with better overall survival and LPFS. One-year LPFS for patients with surgery was 80% and 44% without surgery. Within the 15.4-month follow-up, no grade 3+ toxicity from SABR was observed. No significant quality of life change was observed before and after ICT, SABR, or surgery for BR or LA patients.Conclusions
This is the first prospective phase 2 study to investigate the feasibility and efficacy of a 12-week gemcitabine/capecitabine ICT followed by SABR for BR or LA PDAC. The results suggest excellent tolerability, high R0 resection rates, and acceptable posttreatment complications. 相似文献998.
Carragee EJ Vittum D Truong TP Burton D 《American journal of orthopedics (Belle Mead, N.J.)》1999,28(2):97-102
The purpose of this observation-cohort survey study was to compare the analgesia given and satisfaction with analgesia after a uniform orthopedic injury and operation in culturally disparate settings. Twenty-five patients with isolated closed femoral shaft fractures treated with intramedullary rod fixation within 1 week of injury were retrospectively evaluated at two urban hospitals in the United States. They were compared with a matched group from three urban hospitals in Vietnam (two in Hanoi and one in Ho Chi Minh City [Saigon]). Ages and sex did not differ significantly between the two groups. The mean weight of the Vietnamese group was significantly less than that of the US group (58 vs. 81 kg). During the 14 days following injury, the Vietnamese and American groups were given a mean of 0.9 mg/kg per day versus 30.2 mg/kg per day of morphine equivalent units, respectively. Two (8%) of the Vietnamese group felt their pain control had been inadequate, versus 20 (80%) of the US group. Similarly, 2 (8%) of the US group and 7 (28%) of the Vietnamese group felt they had received "too much" pain medication. Mean heart rates during the first 5 days after surgery were not significantly different in the two groups. Only 4% of the US group felt they had had an accurate impression of how much a femur fracture would hurt prior to the injury, whereas 76% of Vietnamese patients responded that they imagined such an injury would be approximately as painful as it was. Results were similar for preconceptions of pain as a result of surgery and during the postoperative period. More than 50% of patients from the US group felt there must be some explanation other than the femur fracture to explain the severity of their pain, such as infection, missed injury, hardware failure, or inappropriate medical care. Despite much higher administration of narcotic analgesia, American patients with femoral shaft fractures were much more dissatisfied with their analgesic results. In assessing the recommended dosing for "adequate analgesia" and "analgesic requirements," determinations may depend less upon tissue injury than upon cultural norms and patient expectations. 相似文献
999.
1000.
Kevin Burton William N. Zagotta Ronald J. Baskin 《Journal of muscle research and cell motility》1989,10(1):67-84
Summary A detailed investigation of sarcomere lengthening and shortening during fixed-end tetani has been made along frog muscle fibres stretched over a large range of sarcomere lengths. A variety of sources of error common in such measurements are quantitated and give an uncertainty in sarcomere length of about 53–62 nm. The difference in sarcomere length calculated from the left and right first orders at rest was 21 nm ±16 nm and this is suggested to be a measure of Bragg artefact. The laser diffraction measurements showed that the shortening end regions decrease in size during contraction and that the magnitude of shortening is increased at greater fibre extensions. The average length change and sarcomere length of the central and end regions was 0.10 m (2.85 m) and –0.37 m (2.66 m), respectively. The sarcomere length of the end regions at the end of creep was regularly observed to be <2.1 m. An unexpected finding was the occasional observation of striations in the transition zone between lengthening and shortening regions which remained nearly isometric during a period of tension rise during creep. Measurements of diffraction order linewidth do not suggest increased sarcomere length dispersion in these areas. A smooth transition from shortening to lengthening was always observed. Although our data are in general agreement with the models proposed by Morgan, Mochon and Julian (Biophys. J.
39 (1982) 189–96) and Edman and Reggiani(J. Physiol. (Lond.)
351 (1984) 169–98), specific differences which do exist are discussed. 相似文献